Full Press Release Details
REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics (ASHG) 2025 Annual Meeting, taking place October 14-18 in Boston. As human genetics research increasingly moves from sequence to function, Seer’s presence at ASHG reflects how proteomics is becoming an essential complement to genomics in understanding disease biology and accelerating precision medicine. Seer will host a featured CoLab session and will be represented in multiple scientific presentations demonstrating how the Proteograph®Product Suite enables researchers to translate genomic data into biological and clinical insight.
Seer CoLab Session
Advancing Precision Medicine Through Multi-Omics: Clinical Insights from Xenotransplantation and FibrosisDate/Time:October 16, 2025 | 2:30-3:00 p.m. ETLocation:Theater 1, Exhibit Hall
This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research.
Together, these talks show how proteomics and genomics converge to uncover novel biomarkers, deepen understanding of disease mechanisms, and advance clinical translation.
Scientific Presentations Featuring Seer Technology
In addition to the CoLab session, several independent research groups will present findings generated using Seer’s Proteograph platform, reflecting its growing adoption across global academic and clinical institutions. These studies explore how Seer’s proteomic data can clarify and enhance prior findings from affinity-based methods and integrate with genomic datasets for disease discovery.
“It’s remarkable to see how rapidly proteomics is rising in importance among genomics researchers, as reflected in the many exciting presentations at ASHG,” said Omid Farokhzad, Chair and CEO of Seer. “Proteins are the functional drivers of biology, and the proteome is extraordinarily complex. Empowering researchers to connect genetic variation to biological function through deep, unbiased proteomics at scale will help unlock the next phase of precision medicine. We’re thrilled to see so many researchers choosing Seer’s platform to help them make these connections and discoveries.”
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visitwww.seer.bio.